Studies of Sub-dermal Tissue Necrosis of Meloxicam Agar-Gelatin Implants

Meloxicam is the potential NSAID used in chronic diseases. The present research is an attempt for postoperative surgical care in designing 10 mg Meloxicam sustained release implants. The implants comprising plasticizer glycerin and the polymers like agar and gelatin with different ratios (60:40, 70:30 and 80:20% w/w) were formulated using specially designed stainless steel extruder under aseptic conditions. The formulated Meloxicam subdermal implants were characterized to uniform drug content, weight, thickness, passes free formalin test, sterility test and In vitro release of Meloxicam. Subdermal implants which are treated with formaldehyde for 12 hours were found to be sustained release of drug for a period of 90 hours. In vivo studies in rabbits for polymer histopathically and compatible with surrounding tissue of subdermal region.